Shark Tooth Biotech

Developing treatments for CMT1A

and unlocking solutions for other neuropathies

Support Our Mission

Our Mission

Founded by a father whose son lives with Charcot-Marie-Tooth Disease Type 1A (CMT1A), Shark Tooth is a mission-driven company dedicated to developing treatments for the 1.6 million people worldwide living with CMT1A.

Why now?

CMT1A was successfully treated in mice with an RNA-based treatment in 2017, but the dose was toxic to humans.

Since 2017 there have been a lot of advances in the science of RNA (in part thanks to COVID) which remain largely untested for CMT1A.

These improvements - both in the chemistry and the delivery of the RNA - inherently reduce toxicity and could lead to the first treatment for CMT1A.

What's the impact?

While CMT1A is rare, it's the most common rare disease without any treatment or cure affecting 1.6M people worldwide.

Thanks to government incentives such as the “Orphan Disease Designation”, the TAM for CMT1A is approximately $10B per year in the US alone.

Furthermore, solving CMT1A paves the way for treatments for other peripheral nerve diseases impacting 5M people worldwide.

What's our approach?

We will not reinvent the wheel.

Our focus is not on new drug discovery, but rather on what we call “drug assembly”: partnering with labs to fund the research to validate if their proprietary technology could work for CMT1A.

We’ve validated this business model with several partners, and our first candidate was recently injected in a mouse to assess bio-distribution.

How can you help?

At this pivotal stage, we need your support to transform our vision into reality.

We gratefully welcome both investments and tax-deductible donations to advance our mission.

If you’d like to explore ways to contribute or learn more about supporting our efforts, please reach out: apple@sharktooth.bio.

Together, we can make a difference.

Focus on "Drug Assembly"
rather than "New Drug Discovery"

With support from our scientific advisors from Harvard, Johns Hopkins, and leading biotech executives, we've developed a hypothesis on how to accelerate the path to a treatment for CMT1A.

We are convinced that the technology that will lead to the first treatment for CMT1A already exists -- it just hasn't been applied to CMT1A yet.

As such, our focus is not on new drug discovery, but rather on what we are calling "Drug Assembly": partnering with labs to fund the research to test if their proprietary technology could lead to the first treatment for CMT1A.